Effects of cyclosporin A and a non-immunosuppressive analogue, O-acetyl cyclosporin A, upon the growth of parent and multidrug resistant human lung cancer cells in vitro. by Twentyman, P. R. et al.
Br. J. Cancer (1992). 65, 335 340 © Macmillan Press Ltd.. 1992
Effects of cyclosporin A and a non-immunosuppressive analogue, 0-acetyl
cyclosporin A, upon the growth of parent and multidrug resistant human
lung cancer cells in vitro
P.R. Twentyman', K.A. Wnrght' & H.M. Wallace'
'.MRC Clinical Oncologv and Radiotherapeutics l'nit, Hills Road, Cambridge CB2 2QH; 'Department ofMedicine and
Therapeutics and Biomedical Sciences (Pharmacology), lniversity ofAberdeen, Polwarth Building, Foresterhill, Aberdeen AB9
2ZD, Scotland, LWK.
Summant We have studied the ability of cyclosporin A (CsA) and a non-immunosuppressive analogue.
O-acetyl cvclosporin A (OACsA. B3-243) to inhibit the growth of human lung cancer cells in vitro. Using
continuous drug exposure and the MTT colonrmetric assay to determine cell grow-th we found that CsA
produced partial grow-th inhibition at doses ranging from 0.5 to 3.0 ig ml' (0.4-2.4 riM). At progressivelv
higher doses, complete growth inhibition and in situ cell Iysis were seen. The P-glycoprotein expressing
multidrug resistant (MDR) variant H69 LX4 of the small cell line H69 P was less sensitive to cyclosporins
than the parent line. but this was not true of the non-P-glycoprotein expressing MDR variants of large cell line
COR-L23 or adenocarcinoma line MOR. Sensitivity to OACsA was approximately 2-fold higher than that to
CsA in most of the lines although not in the most sensitive line. COR-L88. Even in COR-L88. exposed to CsA
or OACsA for 24 h. clonogenic cell survival was reduced only to 500O. There was no reduction in polyamine
content of COR-L23 or COR-L88 cells folloWing 48 h of exposure to CsA or OACsA. The effects on cell
growth could not be inhibited bs the addition of exogenous putrescine. nor could they be enhanced bv the
addition of x-difluoromethvlorthinine. It does not appear therefore that inhibition of polvamine synthesis is
the basis of the observed grow-th inhibition.
Cxclosponn A (CsA). a cyclic peptide of 11 amino acids. has
receised much attention as an immunosuppressive drug used
in organ transplantation (Borel et al.. 1976). Whereas its
precise mechanism of action is not fully evaluated. it is
known to bind to a cytoplasmic receptor. cyclophilin (Hand-
schumacher et al.. 1984) which has peptidyl-prolvl cis-trans
isomerase actixity (Fischer et al.. 1989). A specific inhibition
of T-cell proliferation occurs at an early stage following
activation. This results in a failure of T-cells both to express
receptors for IL-2 or to secrete IL-2 (Elliott et al.. 1984:
Prince & John. 1986). The effect is greater on cy.totoxic
T-cells than on suppressor T-cells (Hess et al.. 1981).
Inhibition by CsA of rodent and human leukaemic T-cell
proliferation in vitro has been reported by a number of
laboratories (Foa et al.. 1981: Totterman et al.. 1982: Yana-
gihara & Adler. 1983) and clinical therapy of T-cell disease
has been attempted (Puttick et al.. 1983: Morland et al..
1985). There have also been reports of antiproliferative
effects of CsA in tumour cells of non-T-cell origin, although
these are generally observed at higher doses than found
effective in T-cell studies. In two recent studies of the effect
of CsA in hamster pancreatic and mouse colon cancer cell
lines, it was found that the effects could be blocked by the
addition of the polyamine. putrescine. and enhanced by the
addition of the polyamine biosynthesis inhibitor a-difluoro-
methylorthinine (Saydjari et al.. 1986. 1987).
An additional potential role for CsA in cancer therapy has
recentlv been developed in that the compound has been
found to act as an effective modifier of multidrug resistance
(MDR) both in vitro and in vivo (Slater et al.. 1986: Meador
et al.. 1987: Twentvman et al.. 1987). Addition of CsA to an
agent such as adriamvcin or vincristine can. at least partially.
restore sensitivity to cells in which MDR results from hyper-
expression of P-glycoprotein. This property is also possessed
bv some, but not all. analogues of CsA including non-
immunosuppressive analogues (Twentyman. 1988: Chambers
et al.. 1989). Clinical trials of CsA as a resistance modifier
are in progress (Sonneveld & Nooter. 1990).
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In our studies of CsA and various analogues as resistance
modifiers in human lung cancer cells. we observed anti-
proliferative effects at doses of 5 pg ml-' or less. This paper
describes a series of experiments designed to study these
effects in more detail and to determine whether or not inhibi-
tion of polvamine synthesis is involved.
Materials and methods
Cell lines and culture conditions
The human small cell lung cancer cell line H69 P was origin-
ally supplied by Drs A. Gazdar and D. Carney. NCI Navy
Medical Oncology Branch. Bethesda. MD. USA. An MDR
subline H69 LX4 was dervied in our laboratory by in v-itro
growth in adriamycin (Twentyman et al.. 1986: Reeve et al..
1989). This subline hyperexpresses P-glycoprotein and dem-
onstrates an MDR drug accumulation deficit. The large cell
lung carcinoma line COR-L23 P was derived in our labora-
tory (Baillie-Johnson et al.. 1985) and an MDR subline
COR-L23 R obtained by growth in adriamycin (Twentyman
et al.. 1986). Adeno carcinoma line MOR was originally
supplied by Dr M. Ellison. Ludwig Institute. Sutton. MDR
subline MOR R was also derived by in vitro groowth in
adriamvcin. Both L23 R and MOR R whilst exhibiting an
MDR phenotype and reduced drug accumulation do not
hyperexpress P-glycoproteim (Twentyman et al.. 1986: Reeve
et al.. 1990 and unpublished). The small cell lung cancer line
COR-L88 was derived in this laboratory (Baillie-Johnson et
al.. 1985).
All cells were grown in RPMI 1640 medium (Gibco Bio-
cult Ltd) with 10% foetal calf serum (Seralab Ltd) and
penicillin and streptomycin (00 U ml-' and 100jgml'
respectively. Gibco Biocult Ltd). The small cell lines grew as
floating aggregates in 75 cm- tissue culture flasks (Falcon
Plastics) whilst non-small cell lines grew as attached mono-
layers in similar flasks. All lines were passaged weekly.
Routine tests for mycoplasma contamination were carred
out and gave negative results throughout the period of these
studies.
Disaggregation of small cell cultures was achieved by
repeated pipetting of aggregates. For attached cultures.
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15 min incubation with 0.5% trypsin and 0.02% versene
solution in PBS was used.
Drugs
Cyclosponrn A (CsA) and 0-acetvl cyclosponrn A (OACsA.
B3-243) were kindly supplied by Sandoz (Basle). Putrescine
was obtained from Sigma and a-difluoromethyl orthinine
(cx-DFMO) was a gift from Merrell Dow (Cincinatti, USA).
Cyclosporins were dissolved in absolute ethanol at 5 mg
ml-' and stored at 4°C. Dilution in medium was carried out
immediately before use in experiments and the final ethanol
concentration did not exceed 0.1%. Putrescine and x-DFMO
were dissolved in PBS. Appropriate solvent controls were
used in all experiments.
Drug response assaYs
To determine the sensitivity of the various cell lines to con-
tinuous cyclosponrn exposure we used the MTT colorimetric
assay (Mosmann, 1983) as adapted im our laboratory for use
with human lung cancer cell lines (Twentyman, 1988). Cells
were inoculated into wells on 96 well microtitre plates at
between 103 and I04 cells well in a volume of 200jil. Cyclo-
sporins were added 1 h later in a volume of 10 j.d. After the
required incubation period (1-7 days) 20lp of a 5mgml-'
solution of MTT (Sigma) in PBS was added to each well.
The plates were then re-incubation for 5 h. At the end of this
time the bulk of the medium was removed from each well by
aspiration. For plates containing small cell lines. it was neces-
sary to centrifuge the plates before aspiration in order to
pack the floating aggregates on the bottom of the wells. Two
hundred tlA of DMSO was then added to each well and the
plates agitated for 10 min on a plate shaker. The optical
densities of the wells were then read on a Titertek Multiskan
MCC 340 plate reader at 540 nm.
Clonogenic cell survival assays were also carried out on
cells exposed to cyclosporins for 4 or 24 h. Drugs were added
in a small volume to 25 cm flasks of cells in the exponential
phase of growth. At the end of the exposure period COR-
L23 cells were rinsed three times in PBS and then reduced to
a single cell suspension using a combination of trypsin and
versene as previously described. Aggregates of small cell line
COR-L88 were also dispersed for clonogenic assay using
trYpsin versene. Following cell counting using haemocyto-
meters. appropriate dilutions were made and survival was
assayed using our previously described version (Walls &
Twentyman. 1986) of the Courtenay and Mills (1978) soft
agar assay. This assay uses incubation in low oxygen (5% O.
5% CO,. 90% air) and rat red blood cells as a source of
nutrient to stimulate growth of clonogenic cells. Colonies
containing more than 50 cells were counted after an incuba-
tion period of 3 weeks.
Polvamine determination
Cells for polyamine assay were inoculated into 9 cm plastic
petri dishes at numbers such that control cells would be in
late exponential phase at the time of assay. 3 days later.
Cyclosporins and or putrescine were added to the dishes 2 h
after inoculation. At the time of assay. cells were washed
twice with PBS and reduced to a single cell suspension using
trypsin versene. Cells were resuspended in PBS. counted and
polyamines were then extracted using 0.2 M perchloric acid as
previously descnrbed (Wallace et al.. 1984). The extracts were
stored at - 70°C and thawed immediately prior to polyamine
assay. This was carried out by the hplc method of Wallace et
al. (1988). Results were corrected according to the previously
determined cell numbers and expressed as nmoles l0' cells.
Results
Cell grow-th
Typical cell growth curves as determined using the MTT
assay are shown in Figure 1. In this example it is seen that.
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with increasing dose of either cyclosponrn, the effect increased
from partial growth inhibition to complete growth inhibition
to in situ cell destruction. In wells treated with 10 gml-I
CsA for > 3 days. the total absence of intact cells was
confirmed by visual examination under the inverted micro-
scope. Similar data for the various cell lines are summarised
as ID50 values in Table I.
It may be seen that IDO values for both drugs were clearly
higher in MDR small cell line H69 LX4 than in the parent
line H69/P. This was not, however, true for the non-P-
glycoprotein expressing MDR lines L23/R and MOR R com-
pared with their respective parent lines. ID^ values for
OACsA were generally somewhat lower than those for the
parent compound except in small cell line COR-L88. The
sensitivity of the small cell line COR-L88 was clearly higher
than that of the other lines studied.
Timing of administration
Experiments were carried out using a 6-day MTT assay on
COR-L23 and COR-L88 cells in which exposure to CsA was
for different intervals within the 6 day period. In these
experiments, the medium on all wells was changed to fresh
medium immediately before MTT addition in order to elimi-
nate any artefacts due to different medium conditions in
different wells during the MTT reduction process (Jabbar et
al., 1989). Data for COR-L88 are shown in Table II. Con-
tinuous exposure (throughout the 6 days) was the most
effective treatment. Clear effects were, however, seen for
shorter treatments given at the early part of the 6 day period
whereas relatively little effect was seen at later times. In the
second experiment, the control optical density was monitored
throughout the period of the experiment and was 0.36. 0.57,
0.82, 1.10. 1.44 and 1.57 on days 1-6 respectively. The
relatively small effects at later times are, therefore, compati-
ble with inhibition of increases in optical density seen over
these periods. It is clear, however, that effects of exposure at
early times are greater than would be expected from growth
Table I Growth inhibition by CsA and OACsA
ID,Orygml-,)
Cell line Tipe Parent MDR' CsA OACsA
NCI-H69 P Small cell P 4.5. 3.7 2.0. 1.9
4.0. 1.9
NCI-H69 LX-4 MDR 8.8. 6.1 3.6. 2.4
6.4. 2.3
COR-L23 P Large cell P 8.0. 5.5 4.8. 4.1
COR-L23 R MDR 3.9. 5.1 3.4.6.5
MOR P Adeno- P 10.5. 7.2 4.5. 2.8
MOR R carcinoma MDR 9.3. 8.1 5.5. 3.4
COR-L88 Small cell P 2.1. 1.0 1.7. 1.5
0.7. 1.2 0.9, 1.3
'MDR = multidrug resistant subline. bID-% = drug concentration to
reduce the optical density in the MTT assay to 50% of control at the
time atwhich thecontrol optical density isat itshighest valueduring the
7 day assay period. Each value is taken from a set of dose-response
curves obtained in an independent experiment.
Table n Effect of different protocols of cyclosporin A exposure on
growth of COR-L88 cells
Cyclosporin A 'jig ml-
'
Exposure conditions 5 10
Continuous 0.45, 0.40 0.10. 0.12
day 0-day 1 0.55, 0.60 0.38, 0.42
day 0-day 2 0.53. 0.45 0.27, 0.19
day 0-day 3 0.49, 0.37 0.26, 0.20
day 3-day 6 ND, 0.71 ND. 0.54
day 4-day 6 0.86. 0.75 0.73. 0.71
day 5-day 6 0.98. 1.00 0.90. 1.01
Values are optical density on day 6 as fraction of control. Data are
means from four replicatewells ineach oftwo independent experiments.
ND = not done.
inhibition only during the period of drug exposure. This
presumably reflects a 'recovery time'. perhaps due to residual
bound drug, following the exposure period.
Cell survival
The effect of treating cultures of COR-L23 P or COR-L88
cells with either CsA or OACsA for 4 or 24 h was deter-
mined using clonogenic assay. The results are shown in Table
III. It may be seen that the effects were quite modest.
Although significant effects were seen at 24 h. the reduction
in cell survival was never more than 2-fold.
Effects ofputrescine
To test the hypothesis that growth inhibitory effects of cyclo-
sporins may be due to polyamine depletion. the effect of
adding exogenous putrescine was studied. In preliminary
experiments with H69 P and COR-L88 cells it was found
that. in a 6 day MTT assay. concentrations of putrescine up
to 160gsgml-' (1 mM) had little if any effect on cell growth.
We therefore tested the effect of adding a range of putrescine
doses to either CsA or OACsA in the MTT assay. A typical
data set for H69,P cells is shown in Figure 2. There was
clearly no protective effect produced by adding putrescine to
either cyclosporin. Similar experiments with H69 LX4 and
COR-L88 cells produced similar data and conclusions.
Effect of r-DMFO
Preliminary experiments carried out with this compound in
the MTT assay indicated that. at 0.1 mM. there was no effect
on the growth of H69 P. COR-188 or COR-L23 P cells. At
0.2 and 0.5 mM there were detectable effects. the final optical
densities being between 60 and 80% of control at 0.5 mM.
The effect of combining ca-DMFO with CsA in COR-L88 is
shown in Figure 3. There was clearly no potentiation of the
effect of CsA alone. Similar results were obtained in experi-
ments with H69 P and COR-L23 P cells.
Polv amine levels
Data for the effects of cyclosporins on polyamine levels in
COR-L23 and COR-L88 cells after 72 h treatment are shown
in Tables IV and V. It may be seen that no reductions in
polyamine levels resulted from any of these treatments.
Discussion
Antiproliferative and or cvtotoxic effects of CsA on human T
cell leukaemia cells were reported by Foa et al. (1981) and by
Totterman et al. (1982). The effective doses of CsA in these
studies were 5 and 0.1 tg mlP-I respectively with the drug
being continuously present. A study by Yanagihara and
Adler (1983) found that, in mouse lymphoreticular cell lines.
treated continously with 5 jig ml1- CsA. a total loss of viabi-
lity occurred in T-cell lines, whereas only a small degree of
growth inhibition was seen in non-T cell lines. The first
Table Im Clonogenic cell survival after cyclosporin treatment
Dose Survivingfraction
Cell line Agent (Igml-,) 4 h 24 h
COR-L23 P CsA 5 0.96 (0.05) 0.83 (0.15)
10 0.87 (0.08) 0.56 (0.05)
OACsA 5 1.13 (0.22) 0.84 (0.14)
10 0.97 (0.17) 0.62 (0.06)
COR-L88 5 0.81 (0.09) 0.74a (0.14)
CsA 10 0.78 (0.13) 0.58' (0.16)
OACsA 5 0.90 (0.07) 0.54' (0.17)
10 1.08 (0.14) 0.50- (0.10)
Values are means (s.e.) ofthree or 'five independent determinations,
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Figre 2 Effect of putrescine on the response of H69 P cells to (a) cyclosporin A or b O-acetyl cvclosponrn A as determined by the
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Figre 3 Effect of mDFMO on the response of COR-L88 cells to
cyclosporin A as determined by the MTU assay after 6 days
growth: *. control: 0. DFMO 0.1 iLgml '; A. 0.2 jigml-';
A. 0.5 ;Lg ml-,.
Table IV Polyamine content of COR-L23 P cells
Treatment Putrescine Spermidine Spermine Total % Control
Control 0.2 1.1 4.4 5.7 100
0.4 2.2 4.0 6.6 100
CsA
Ijigml'i 0.3 1.4 5.7 7.4 128
0.5 2.6 3.8 6.9 104
2jugml-' 0.2 1.2 5.0 6.4 112
0.5 2.7 5.6 8.8 133
4jigmlr- 0.2 1.1 4.7 6.0 103
0.5 2.9 4.9 8.3 125
OACsA
0.5 jig ml-' 0.8 3.1 6.1 10.0 152
1.0ilgml 0.2 1.2 4.7 6.1 105
0.5 2.4 4.9 7.8 118
2.0 jigml-' 0.6 2.3 7.4 10.3 180
0.6 3.3 5.8 9.7 146
Expressed as nmoles per 106 cells. Each value is the mean of two
replicate determinations. Data for two independent experiments are
shown.
report of a possible antitumour activity for CsA was by Kreis
and Sonrcelli (1979). They found that repeated daily injec-
tions of the agent could inhibit the in vivo growth of a
number of murine ascites tumours. These effects were obtain-
ed at doses close to the toxic limit. Although the authors
described their results as 'promising', little further investiga-
TableV Polyamine content of COR-L88 cells
Treatment Putrescine Spermidine Spermine Total % Control
Control 0.1 0.7 1.1 1.9 100
0.2 0.9 0.7 1.8 100
CsA
0.25 Lg ml' 0.2 1.0 0.6 1.8 100
0.5 ILg ml-' 0.1 2.0 2.4 4.3 226
0.2 1.3 0.8 2.3 127
1.0 jig ml' 0.0 1.0 1.3 2.3 121
0.2 1.2 0.9 2.3 128
OACsA
0.25 Lg ml' 0.2 1.2 0.9 2.3 128
0.5 iLgmml 0.0 1.1 1.6 2.7 142
0.2 1.3 1.3 2.8 156
1.0 iLg ml-, 0.0 0.9 1.1 2.0 105
0.2 0.8 1.1 2.1 117
Expressed as nmoles per 106 cells. Each value is the mean of two
replicate determinations. Data for two independent experiments are
shown.
tion of a possible antitumour activity for cyclosporins in iiho
appears to have occurred.
The results reported in this paper indicate that effects of
CsA and OACsA are seen in human lung cancer cells only
when the agents are present for prolonged periods of time
and that the doses required to produce these effects are in the
range 0.5-10;jg ml'. Even in the relatively sensitive cell line
COR-L88, a 24h exposure to 10igrml-' of either cyclo-
sporin produced no more than a 2-fold reduction in clono-
genic cell survival. These results are very different to those of
Totterman et al. (1982) who observed extensive cytolysis
within 24 h of human leukaemic T cells treated with 5 jg
ml-' CsA. However, our results in the MTT assay, by the
standard endpoint of formazan reduction and confirmed by
visual observation of the wells indicates that, at higher doses
(>5ig ml-') for longer periods of time (>72 h), complete
loss of cell viability occurs. In the clinical use of CsA as an
immunosuppressive agent, a rapid initial phase of plasma
clearance occurs following the attainment of peak levels of
1-2 jig ml-1 (Kahan et al., 1983). Levels during the pro-
longed second plateau phase are very much lower (-0.1 jig
ml-'). It appears unlikely therefore that the results which we
report here in which continuous exposure to at least 1.0 iLg
ml-' was required for growth inhibition are of significance
for the use of CsA as an anticancer agent. Nevertheless there
is clearly a heterogeneity of sensitivity amongst lung cell lines
and furthermore, OACsA in most of the lines studied is
approximately 2-fold more potent than CsA.
Based on a report by Fidelius et al. (1984) that CsA could
act as an inhibitor of orthinine decarboxylase and therefore
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of polyamine synthesis. Saydjari et al. (1986, 1987) imvesti-
gated the in vitro effects of combining CsA with a-DFMO. a
known inhibitor of polyamine synthesis. They studied the
growth of hamster pancreatic and mouse colon carcinoma
cells in vitro and at CsA doses of 1 and 5 gml-'. In both
series of experiments, a small inhibition of cell growth by
CsA was reported which was both reversible by the addition
of exogenous putrescine (0.05 mM) and synergistic with the
effects of a-DFMO. In one of the studies the effects of CsA
(lJLg ml-') upon polyamine levels were studied after 72 h
exposure. Three and 2-fold reductions in levels of spermidine
and spermine respectively were seen (Saydjari et al., 1986). In
contrast to these data. McLachlan et al. (1991) have shown
that. in MOLT4 T-lymphoblastic leukaemia cells, where a
transient decrease in ODC activity was produced by exposure
to CsA (2.5 or 5pg ml-'), there was no significant change in
polyamine concentrations after 48 or 96 h of exposure. More-
over, growth inhibitory effects of CsA were unaffected by the
addition of putrescine at concentrations between 0.1 and
10 mM. These data are therefore in agreement with the results
which we present in this paper.
Following a description of its ability to act as a modifier of
multidrug resistance (Slater et al., 1986: Twentyman et al..
1987) CsA was shown to bind to P-glycoprotein. the putative
drug efflux pump molecule involved in the MDR phenotype
(Foxwell et al.. 1989). It has also been demonstrated that
MDR Chinese hamster cells accumulate less tritium-labelled
CsA than the corresponding parent cells (Goldberg et al.,
1988). The clear reduction in CsA sensitivity seen in H69
LX4 (P-glycoprotein positive) compared with H69 P (P-
glycoprotein negative) may therefore be accounted for by a
similar differential CsA accumulation in this pair ofcell lines.
In our pairs of cell lines where the MDR phenotype occurs in
the absence of P-glycoprotein. no such differential was seen.
The experiments which we have carried out do not clarify
the mechanism whereby cyclosporins can inhibit cell growth.
It is known that CsA binds to a specific cytosolic protein.
cyclophilin (Hardschumacher et al., 1984) and that this pro-
tein has peptidyl-prolyl cis-trans isomerase activity (Fischer
et al.. 1989). It has been recently suggested that such inter-
actions may interfere with the activity of protein kinase C
and cell signal transduction (Tropschug & Hoffman. 1991). A
number of groups have also reported effects of CsA on the
physico-chemical properties of the plasma membrane. The
drug binds to phospho-lipid vesicles, thereby disrupting
membrane architecture (Haynes et al.. 1985) and interferes
with the incorporation of fatty acids into the plasma mem-
brane phospholipids of activated T-cells (Szamel et al.. 1986).
It also depolarises cytoplasmic membrane potentials (Matyus
et al.. 1986).
In conclusion. therefore. we have shown that CsA and
OACsA will each inhibit growth of human lung cancer cells
in *itro. but only at doses in excess of those which are
clinically achievable. OACsA is. however, more potent than
the parent compound and as further analogues enter clinical
trial as possible resistance modifiers therefore. the possibility
that antitumour effects of the cyclosporin alone may occur
should be borne in mind.
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